Amplia Therapeutics Management
Management criteria checks 3/4
Amplia Therapeutics' CEO is Chris Burns, appointed in Dec 2022, has a tenure of 1.92 years. total yearly compensation is A$407.91K, comprised of 70.3% salary and 29.7% bonuses, including company stock and options. directly owns 1.35% of the company’s shares, worth $210.06K. The average tenure of the management team and the board of directors is 1.9 years and 5.6 years respectively.
Key information
Chris Burns
Chief executive officer
AU$407.9k
Total compensation
| CEO salary percentage | 70.3% |
| CEO tenure | 1.9yrs |
| CEO ownership | 1.4% |
| Management average tenure | 1.9yrs |
| Board average tenure | 5.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | AU$408k | AU$287k | -AU$5m |
| Dec 31 2023 | n/a | n/a | -AU$4m |
| Sep 30 2023 | n/a | n/a | -AU$4m |
| Jun 30 2023 | n/a | n/a | -AU$5m |
| Mar 31 2023 | AU$2m | AU$106k | -AU$6m |
| Dec 31 2022 | n/a | n/a | -AU$6m |
| Sep 30 2022 | n/a | n/a | -AU$5m |
| Jun 30 2022 | n/a | n/a | -AU$4m |
| Mar 31 2022 | AU$22k | n/a | -AU$4m |
| Dec 31 2021 | n/a | n/a | -AU$3m |
| Sep 30 2021 | n/a | n/a | -AU$3m |
| Jun 30 2021 | n/a | n/a | -AU$3m |
| Mar 31 2021 | AU$20k | n/a | -AU$2m |
| Dec 31 2020 | n/a | n/a | -AU$2m |
| Sep 30 2020 | n/a | n/a | -AU$2m |
| Jun 30 2020 | n/a | n/a | -AU$2m |
| Mar 31 2020 | AU$20k | n/a | -AU$2m |
Compensation vs Market: Chris's total compensation ($USD264.71K) is below average for companies of similar size in the US market ($USD647.72K).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Burns (60 yo)
1.9yrs
Tenure
AU$407,911
Compensation
Dr. Christopher J. Burns, also known as Chris, B.Sc. (Hons), Ph.D. FRACI FRSC, GAICD, serves as the CEO of MetabloQ Pty Ltd. Dr. Burns served as an Independent Non-Executive Director of Amplia Therapeutics...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 1.9yrs | AU$407.91k | 1.35% $ 210.1k | |
| Chief Financial Officer | 1.2yrs | no data | no data | |
| Chief Operating Officer | no data | no data | no data | |
| Company Secretary | 11.1yrs | AU$113.95k | no data |
1.9yrs
Average Tenure
Experienced Management: INNM.F's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 6.5yrs | AU$407.91k | 1.35% $ 210.1k | |
| Independent Non-Executive Chairman | 6.5yrs | AU$70.00k | 1.34% $ 207.6k | |
| Independent Non-Executive Director | 9.2yrs | AU$50.00k | 1.6% $ 248.0k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 3.6yrs | AU$50.00k | 1.03% $ 160.1k | |
| Member of Scientific Advisory Board | 2.8yrs | no data | 0.81% $ 125.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
5.6yrs
Average Tenure
67.5yo
Average Age
Experienced Board: INNM.F's board of directors are considered experienced (5.6 years average tenure).